A rise in saliva and urine pH in children with SCN1A-related epilepsy: An exploratory prospective controlled study

Qian Lu1,2, Yang-Yang Wang1,2, Hui-Min Chen1,2

  • 1Senior Department of Pediatrics, Chinese PLA General Hospital, Beijing, China.

Frontiers in Neurology
|October 14, 2022
PubMed

Insights

Children with SCN1A-related epilepsy show higher saliva and urine pH. This pH elevation is particularly notable in those experiencing seizures and Dravet syndrome, suggesting a potential biomarker for epilepsy severity.

Area of Science:

  • Neurology
  • Genetics
  • Biochemistry

Background:

  • SCN1A gene mutations are linked to various epilepsy syndromes.
  • Altered physiological parameters may be associated with SCN1A-related epilepsies.

Purpose of the Study:

  • To investigate salivary and urinary pH levels in pediatric patients with SCN1A-related epilepsy.
  • To compare pH values between epileptic children and healthy controls.

Main Methods:

  • A prospective, controlled observational study involving seven children with SCN1A-related epilepsy and seven healthy controls.
  • Saliva and urine pH were measured using pH test paper over 21-95 days.
  • Seizure occurrences were recorded to correlate with pH changes.

Main Results:

  • Participants were 14 males aged 1-14 years, with seven patients having pathogenic SCN1A variants.
  • Saliva and urine pH were consistently higher in the SCN1A-related epilepsy group compared to controls.
  • Elevated urine pH was observed in patients with Dravet syndrome and in those experiencing seizures during the study.

Conclusions:

  • Patients with SCN1A-related epilepsy exhibit chronically elevated saliva and urine pH.
  • Higher urine pH correlates with seizure activity and Dravet syndrome within this patient cohort.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
253
Salivary Glands and Saliva01:23

Salivary Glands and Saliva

The salivary glands, of which there are three pairs known as the parotid, submandibular, and sublingual glands, play a crucial role in maintaining oral health and initiating the digestive process. Positioned near the ears, beneath the masseter muscle, the parotid glands secrete saliva into the oral cavity through the parotid duct of Stensen. Meanwhile, the submandibular glands, located on the floor of the mouth, secrete saliva through channels named submandibular ducts. The sublingual glands,...
852
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
810
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
413